<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Surg</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Surg</journal-id>
      <journal-title-group>
        <journal-title>BMC Surgery</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2482</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26226942</article-id>
      <article-id pub-id-type="pmc">4520015</article-id>
      <article-id pub-id-type="publisher-id">76</article-id>
      <article-id pub-id-type="doi">10.1186/s12893-015-0076-3</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Baur</surname>
            <given-names>Johannes</given-names>
          </name>
          <address>
            <email>baur_j@ukw.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schedelbeck</surname>
            <given-names>Ulla</given-names>
          </name>
          <address>
            <email>schedelbec_u@ukw.de</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pulzer</surname>
            <given-names>Alina</given-names>
          </name>
          <address>
            <email>pulzer_a@ukw.de</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bluemel</surname>
            <given-names>Christina</given-names>
          </name>
          <address>
            <email>bluemel_c@ukw.de</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wild</surname>
            <given-names>Vanessa</given-names>
          </name>
          <address>
            <email>vanessa.wild@uni-wuerzburg.de</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fassnacht</surname>
            <given-names>Martin</given-names>
          </name>
          <address>
            <email>fassnacht_m@ukw.de</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Steger</surname>
            <given-names>U.</given-names>
          </name>
          <address>
            <email>klausulrich.steger@googlemail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of General, Visceral, Vascular and Pediatric Surgery, University Hospital Wuerzburg, Wuerzburg, Germany </aff>
        <aff id="Aff2"><label/>Institute of Radiology, University Hospital Wuerzburg, Wuerzburg, Germany </aff>
        <aff id="Aff3"><label/>Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany </aff>
        <aff id="Aff4"><label/>Department of Internal Medicine I, Endocrinology, University Hospital Wuerzburg, Wuerzburg, Germany </aff>
        <aff id="Aff5"><label/>Comprehensive Cancer Center Mainfranken, University of Wuerzburg, Wuerzburg, Germany </aff>
        <aff id="Aff6"><label/>Institute of Pathology, University Wuerzburg, Wuerzburg, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>7</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>31</day>
        <month>7</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>15</volume>
      <elocation-id>93</elocation-id>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>4</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>7</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Baur et al. 2015</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Solitary metastases to the pancreas are rare. Therefore the value of resection in curative intention remains unclear. In the literature there are several promising reports about resection of solitary metastasis to the pancreas mainly of renal origin.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>Here we report for the first time on the surgical therapy of a 1.5&#xA0;cm solitary pancreatic metastasis of an adrenocortical carcinoma. The metastasis occurred almost 6&#xA0;years after resection of the primary tumor. A partial pancreatoduodenectomy was performed and postoperatively adjuvant mitotane treatment was initiated. During the follow-up of 3&#xA0;years after surgery no evidence of tumor recurrence occurred.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Resection of pancreatic tumors should be considered, even if the mass is suspicious for metastatic disease including recurrence of adrenocortical cancer.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Adrenocortical Carcinoma</kwd>
        <kwd>Metastases to pancreas</kwd>
        <kwd>Surgical treatment</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Adrenocortical carcinoma (ACC) is a rare malignant tumor with an estimated incidence of 1 to 2 cases per million population [<xref ref-type="bibr" rid="CR1">1</xref>]. The occurrence has a first peak in childhood and a second in the fourth and fifth decade of life. The majority of ACC are sporadic. But in some cases ACC is part of hereditary syndromes like Li-Fraumeni syndrome, Beckwith-Wiedeman syndrome, multiple endocrine neoplasia (MEN) 1, congenital adrenal hyperplasia or familial polyposis coli [<xref ref-type="bibr" rid="CR2">2</xref>]. Therapy and prognosis strongly depend on the European Network for the Study of Adrenal Tumours (ENSAT) classification [<xref ref-type="bibr" rid="CR3">3</xref>]. In localized disease, surgery is treatment of choice [<xref ref-type="bibr" rid="CR4">4</xref>], whereas in advanced disease mitotane alone or in combination with cytotoxic drugs is standard of care [<xref ref-type="bibr" rid="CR5">5</xref>]. According to the German ACC register, 5-year-survival rates are 84&#xA0;%, 63&#xA0;%, 51&#xA0;% and 15&#xA0;% for Stage I, II, III and IV respectively [<xref ref-type="bibr" rid="CR6">6</xref>]. Management of recurrent disease is not standardized [<xref ref-type="bibr" rid="CR5">5</xref>], but recent retrospective studies suggest that surgery is of benefit in selected cases [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
      <p>Metastatic involvement of pancreas due to any primary malignant tumor is rare and represents about 2&#xA0;% of all pancreatic tumors. Most of these patients show diffuse distant metastases of their primary tumor [<xref ref-type="bibr" rid="CR8">8</xref>] with no opportunity of surgical treatment.</p>
      <p>Here, we present a case of recurrent ACC with a solitary pancreatic metastasis 6&#xA0;years after resection of the primary tumor.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 45-year-old woman was first diagnosed in 2006 with ACC showing typical signs of Cushing&#x2019;s syndrome with consecutive increase of weight and body hair, acne, therapy-refractory arterial hypertension and decrease of physical working capacity. Hormonal work-up revealed elevated cortisol levels basal and after dexamethasone suppression, as well as elevated dehydroepiandrosterone sulphate (DHEA-S) and androgen levels. CT scan showed a 4.7 &#xD7; 5.2 &#xD7; 4.5&#xA0;cm sized mass of the left adrenal gland with venous contrast enhancement suspicious for adrenocortical carcinoma (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Imaging of the primary adrenocortical carcinoma (<bold>a</bold>) and the solitary metachronous metastasis inside the pancreatic head (<bold>b</bold>) by MRT and FDG-PET/CT, respectively</p></caption><graphic xlink:href="12893_2015_76_Fig1_HTML" id="MO1"/></fig></p>
      <p>The patient underwent conventional resection of the left adrenal gland and lymphadenectomy. Pathological study of the resected tissue was performed by two independent pathologists. The tumor presented a solid growth pattern with some fibrous bands and small areas of necrosis. Tumor cells appeared monomorphic with small nuclei and condensated chromatin. The rate of mitosis was under 1 in 10 high power fields. Interestingly there were large amounts of myelolipomatosis metaplastic areas. All three classic scoring systems showed results still within the value range for benign lesions. However, a high Ki-67 expression of 20&#xA0;% led to the diagnosis of an adrenocortical carcinoma (ENSAT stage II). Due to a good differentiation, no adjuvant mitotane therapy has been performed. Though the patient underwent follow-up examinations periodically, including hormonal work-up and CT or MR imaging performed initially every 3&#xA0;months and eventually every 6&#xA0;months after a 2-year-recurrence-free survival.</p>
      <p>Sixty-six months after surgical treatment MR imaging showed a new hyperperfused mass in the head of the pancreas with progression of size in the following studies as well as a high FDG-uptake in positron emission tomography (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Thus, the mass was highly suspicious of malignancy and resection was recommended by interdisciplinary consensus.</p>
      <p>The patient underwent pylorus preserving partial pancreaticoduodenectomy. Postoperatively the patient developed a pancreatic fistula with an intraabdominal abscess formation, which had to be drained interventionally on day 10 after surgery. The drain could be removed on day 24 after surgery.</p>
      <p>Histological and immunohistochemical examination of the resected tissue showed a 1.5&#xA0;cm sized well differentiated tumor with solid growth pattern (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>). Tumor cells presented monomorphic with eosinophilic cytoplasm and unremarkable nuclei. The metastasis stained positive for synapthophysin, Melan A and steroidogenic factor 1 (SF-1) in consistency with the diagnosis as a metastasis of the adrenocortical carcinoma (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2b</xref>) with a Ki-67 expression in 10&#xA0;% of tumor cells. There where no signs of a primary pancreatic carcinoma as the tumor cells stained negative for pan cytokeratine (pan-ck) (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>). In addition, pathological examination by the reference pathologist of the German ACC study group was performed and confirmed the correlation between the ACC primary tumor and the unusual site of metastasis.<fig id="Fig2"><label>Fig. 2</label><caption><p>Histology of pancreatic mass (<bold>a</bold>) metastasis with adjacent pancreatic tissue (*) (HE stain, 20x) (<bold>b</bold>) ACC metastasis with nuclear positive staining pattern for SF-1 (SF1, 40x) (<bold>c</bold>) ACC metastasis with positive cytoplasmic staining for Synaptophysin (<bold>d</bold>) ACC metastasis with positive cytoplasmic staining for Inhibin [E] ACC metastasis is negative for pan-ck (AE1/3, 20x), the pancreatic acini stain positive for pan-ck</p></caption><graphic xlink:href="12893_2015_76_Fig2_HTML" id="MO2"/></fig></p>
      <p>According to interdisciplinary consensus an adjuvant mitotane therapy was initiated after the tumor resection and is still ongoing. During follow-up, including endocrine and imaging work-up every 3&#xA0;months now for more than 3&#xA0;years, there is no evidence of recurrence (Time axis see Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Time axis</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>2006</td><td>Conventional left-side Adrenalectomie of an Adrenocortical Carcinoma (stadium II, diameter 7&#xA0;cm)</td></tr><tr><td>2006 - 2012</td><td>Unsuspicious follow-up in periodically performed cross-sectional studies</td></tr><tr><td>02/2012</td><td>Detection of a pancreatic mass suspicious for malignancy in PET</td></tr><tr><td>03/2012</td><td>Pylorus preserving partial pancreaticoduodenectomy Histological and immunhistochemic examination showed a 1.5&#xA0;cm sized well differentiated metastasis of the adrenocortical carcinoma</td></tr><tr><td>Till present date</td><td>Mitotane Therapy, unsuspicious follow-up in periodically performed cross-sectional studies and hormonal work-up</td></tr></tbody></table></table-wrap></p>
      <sec id="Sec3">
        <title>Literature review</title>
        <p>A literature review has been performed to identify the distribution of different tumor entities of solitary metastases inside the pancreas. A PubMed search for studies or case reports dealing with &#x201C;metastases to pancreas&#x201D; was performed. Articles were included in this review if 10 or more patients were investigated retrospectively or prospectively, patients suffered of metastases to pancreas (no infiltrative involvement) and only the pancreas was affected by metastases, patients received resection of pancreas metastases in curative intension and different tumor entities were included in each study. Four retrospective studies [<xref ref-type="bibr" rid="CR9">9</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>] summerized in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref> met the inclusion criteria with a total of 92 patients. Median age of patients ranged from 59 to 64&#xA0;years. Most frequent origin of pancreatic metastases was the kidney in 46&#xA0;% of the cases followed by melanoma in about 10&#xA0;% of the cases. Rectal and Colon carcinomas were involved in only 5 cases. One &#x201C;non-pancreatic endocrine tumor&#x201D; was reported but not specified in more detail [<xref ref-type="bibr" rid="CR12">12</xref>]. Here, the distribution of metastatic origin is different to other literature reviews, where the proportion of renal cell carcinomas range between 60 and 70&#xA0;% [<xref ref-type="bibr" rid="CR8">8</xref>]. This is caused by the exclusion of studies intending to investigate a single tumor entity metastatic to the pancreas (mostly renal cell carcinomas). Median survival after curative resection of pancreatic metastases was 2.2 to 4.3&#xA0;years. 5-year-survival ranged between 36&#xA0;% and 61&#xA0;%.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Literature review</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Author (Year)</th><th>Years observed</th><th>No. of patients</th><th>Median age</th><th>Median survival (y)</th><th>5-year- survival (y)</th><th>RCC</th><th>Melanoma</th><th>Gall bladder</th><th>Sarcoma</th><th>Colon</th><th>Ovar</th><th>Lung</th><th>Breast</th><th>Others<sup>a</sup>
</th></tr></thead><tbody><tr><td>Reddy el al. (2008) [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td>1970&#x2013;2007</td><td>49</td><td>60</td><td>3.7</td><td>36&#xA0;%</td><td>21 (42.9)</td><td>3(6.1)</td><td>6 (12.2)</td><td>4 (8.2)</td><td>2 (4.1)</td><td>4(8.1)</td><td>4 (8.2)</td><td>1 (2.0)</td><td>4(8.1)</td></tr><tr><td>Bahra ct al. (2008) [<xref ref-type="bibr" rid="CR7">7</xref>]</td><td>1989&#x2013;2007</td><td>20</td><td>62</td><td>not reached</td><td>61&#xA0;%</td><td>9 (45.0)</td><td>1 (5.0)</td><td>1 (5.0)</td><td>2 (10 .0)</td><td>1 (5.0)</td><td>-</td><td>-</td><td>-</td><td>6(12.2)</td></tr><tr><td>Eidt ct al. (2007) [<xref ref-type="bibr" rid="CR9">9</xref>]</td><td>1993&#x2013;2005</td><td>12</td><td>64</td><td>4.3</td><td>not reported</td><td>7(58.3)</td><td>4(33.1)</td><td>-</td><td>-</td><td>1 (8.3)</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Crippa ct al. (2006) [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td>1994&#x2013;2005</td><td>11</td><td>59</td><td>2.2</td><td>48&#xA0;%</td><td>5 (45.5)</td><td>1(9.1)</td><td>-</td><td>-</td><td>1 (9.1)</td><td>1(9.1)</td><td>-</td><td>3 (27.3)</td><td>-</td></tr><tr><td/><td/><td>92</td><td/><td/><td/><td>42(45.7)</td><td>9.(9.8)</td><td>7(7.6)</td><td>6(6.5)</td><td>5(5.4)</td><td/><td>4(4.3)</td><td>4(4.3)</td><td>10(10.9)</td></tr></tbody></table><table-wrap-foot><p>
<italic>RCC</italic> Renal cell careinoma</p><p>
<sup>a</sup>Schwannoma (reported twice); Seminoma, Teratocarcinoma, Hepatocellular Carcinoma, Langerhans cell histiocytosis, esophagus, mesechymal gastric tumor, non-pancreatic endocrine tumor (not specified), GIST (each one case reported)</p></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec4" sec-type="discussion">
      <title>Discussion</title>
      <p>Solitary metastases to the pancreas are rare. Only 1.3&#xA0;% of patients undergoing pancreatic resection present a solitary metastasis of a primary solid tumor [<xref ref-type="bibr" rid="CR12">12</xref>]. In our literature review singular metastasis to the pancreas was most frequent of renal origin (46&#xA0;% of cases). The value of resection in curative intention remains unclear. As our literature review revealed, 5-year-survival may range between 36&#xA0;% and 61&#xA0;% if different tumor entities are taken together. Certain metastatic tumor entities even show better survival rates after curative resection compared to primary pancreatic carcinomas. In case of a singular pancreatic metastasis of renal cell carcinoma a 5-year-survival between 66&#xA0;% and 79&#xA0;% can be achieved by curative resection of pancreatic metastasis [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p>
      <p>Here we report for the first time a case of a solitary pancreatic metastasis of an adrenocortical carcinoma. ACC is one of the most aggressive endocrine tumors known so far. Resection of recurrent tumor is recommended in selected case (e.g. when the disease-free interval exceeds 12&#xA0;months and complete resection seems to be feasible) [<xref ref-type="bibr" rid="CR7">7</xref>]. In our case, the metastasis occurred almost 6&#xA0;years after resection of a very well differentiated primary tumor and a R0 resection could be performed. Although known to improve recurrence-free survival after resection of primary tumor [<xref ref-type="bibr" rid="CR14">14</xref>], it remains unclear if adjuvant mitotane therapy would have prevented recurrence of ACC. However, the patient would have suffered from mitotane side effects like adrenocortical insufficiency. As the patient is now again free of disease for more than 3&#xA0;years, surgical approach to treat solitary pancreatic ACC metastasis was most likely of great benefit to her.</p>
    </sec>
    <sec id="Sec5" sec-type="conclusions">
      <title>Conclusion</title>
      <p>In conclusion, resection of pancreatic tumors should be considered, even if the mass is suspicious for metastatic disease including recurrence of adrenocortical cancer.</p>
      <sec id="Sec6">
        <title>Consent</title>
        <p>Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ACC</term>
          <def>
            <p>Adrenocortical carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>ENSAT</term>
          <def>
            <p>European Network of the Study of Adrenal Tumours</p>
          </def>
        </def-item>
        <def-item>
          <term>DHEA-S</term>
          <def>
            <p>Dehydroepiandrosterone sulphate</p>
          </def>
        </def-item>
        <def-item>
          <term>SF-1</term>
          <def>
            <p>Steroidogenic factor 1</p>
          </def>
        </def-item>
        <def-item>
          <term>pan-ck</term>
          <def>
            <p>Pancreatic cytoceratine</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>JB was involved in postoperative care of the patient after pancreatic resection, wrote the case report, made literature review and drafted the manuscript. US and CB were the main persons involved in preoperative detection of pancreatic mass and revised the manuscript. MF and AP were involved in diagnosis, adjuvant treatment and follow-up before and after resection of primary tumor and metastasis to the pancreas. Both revised the paper. VW performed conventional and immunohistochemical staining of pancreatic ACC metastasis and revised the manuscript. US performed pancreatic resection, was involved in postoperative care of the patient and revised the manuscript. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding program Open Access Publishing.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fassnacht</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kroiss</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Allolio</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Update in adrenocortical carcinoma</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2013</year>
          <volume>98</volume>
          <fpage>4551</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2013-3020</pub-id>
          <pub-id pub-id-type="pmid">24081734</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fassnacht</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Libe</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kroiss</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Allolio</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Adrenocortical carcinoma: a clinician's update</article-title>
          <source>Nat Rev Endocrinol</source>
          <year>2011</year>
          <volume>7</volume>
          <fpage>323</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1038/nrendo.2010.235</pub-id>
          <pub-id pub-id-type="pmid">21386792</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fassnacht</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Johanssen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Quinkler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bucsky</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Willenberg</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Beuschlein</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification</article-title>
          <source>Cancer</source>
          <year>2009</year>
          <volume>115</volume>
          <fpage>5847</fpage>
          <pub-id pub-id-type="doi">10.1002/cncr.24693</pub-id>
          <pub-id pub-id-type="pmid">19827149</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="other">Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7.</mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Else</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Sabolch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Raymond</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Kandathil</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Caoili</surname>
              <given-names>EM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Adrenocortical carcinoma</article-title>
          <source>Endocr Rev</source>
          <year>2014</year>
          <volume>35</volume>
          <fpage>282</fpage>
          <lpage>326</lpage>
          <pub-id pub-id-type="doi">10.1210/er.2013-1029</pub-id>
          <pub-id pub-id-type="pmid">24423978</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fassnacht</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Allolio</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Clinical management of adrenocortical carcinoma</article-title>
          <source>Best Pract Res Clin Endocrinol Metab</source>
          <year>2009</year>
          <volume>23</volume>
          <fpage>273</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="doi">10.1016/j.beem.2008.10.008</pub-id>
          <pub-id pub-id-type="pmid">19500769</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Erdogan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Deutschbein</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jurowich</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kroiss</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ronchi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Quinkler</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The role of surgery in the management of recurrent adrenocortical carcinoma</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2013</year>
          <volume>98</volume>
          <fpage>181</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2012-2559</pub-id>
          <pub-id pub-id-type="pmid">23150691</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reddy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wolfgang</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>The role of surgery in the management of isolated metastases to the pancreas</article-title>
          <source>Lancet Oncol</source>
          <year>2009</year>
          <volume>10</volume>
          <fpage>287</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(09)70065-8</pub-id>
          <pub-id pub-id-type="pmid">19261257</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bahra</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jacob</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Langrehr</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Glanemann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schumacher</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lopez-Hanninen</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Metastatic lesions to the pancreas. When is resection reasonable?</article-title>
          <source>Chirurg</source>
          <year>2008</year>
          <volume>79</volume>
          <fpage>241</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1007/s00104-007-1390-9</pub-id>
          <pub-id pub-id-type="pmid">17717640</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crippa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Angelini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mussi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bonardi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sartori</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Surgical treatment of metastatic tumors to the pancreas: a single center experience and review of the literature</article-title>
          <source>World J Surg</source>
          <year>2006</year>
          <volume>30</volume>
          <fpage>1536</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.1007/s00268-005-0464-4</pub-id>
          <pub-id pub-id-type="pmid">16847716</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eidt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jergas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Siedek</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Metastasis to the pancreas--an indication for pancreatic resection?</article-title>
          <source>Langenbecks Arch Surg</source>
          <year>2007</year>
          <volume>392</volume>
          <fpage>539</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.1007/s00423-007-0148-7</pub-id>
          <pub-id pub-id-type="pmid">17242893</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reddy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Edil</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Cameron</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Pawlik</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Herman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Gilson</surname>
              <given-names>MM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pancreatic resection of isolated metastases from nonpancreatic primary cancers</article-title>
          <source>Ann Surg Oncol</source>
          <year>2008</year>
          <volume>15</volume>
          <fpage>3199</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="doi">10.1245/s10434-008-0140-7</pub-id>
          <pub-id pub-id-type="pmid">18784960</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yuasa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Inoshita</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Saiura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Urakami</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Masuda</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical outcome of patients with pancreatic metastases from renal cell cancer</article-title>
          <source>BMC Cancer</source>
          <year>2015</year>
          <volume>15</volume>
          <fpage>46</fpage>
          <pub-id pub-id-type="doi">10.1186/s12885-015-1050-2</pub-id>
          <pub-id pub-id-type="pmid">25872621</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Terzolo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Angeli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fassnacht</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Daffara</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tauchmanova</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Conton</surname>
              <given-names>PA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Adjuvant mitotane treatment for adrenocortical carcinoma</article-title>
          <source>N Engl J Med</source>
          <year>2007</year>
          <volume>356</volume>
          <fpage>2372</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa063360</pub-id>
          <pub-id pub-id-type="pmid">17554118</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
